title: The role of iron chelation therapy for patients with myelodysplastic syndromes.
abstract: The appropriate role of iron chelation therapy in the management of patients with myelodysplastic syndromes (MDS) is currently controversial. Some investigators interpret data to indicate that careful attention to iron parameters, with early initiation of iron chelation in patients with evidence suggesting transfusion-associated iron overload, is an important component of high-quality MDS patient care. Other physicians are more skeptical, noting that chelation can be cumbersome or costly, has associated risks, and has not yet been shown to reduce morbidity or mortality in the MDS setting. This article reviews the extent to which iron chelation therapy might be either an important clinical intervention in MDS or a distraction from more pressing clinical concerns.
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachussets 02115, USA. david_steensma@dfci.harvard.edu
authors.forename: David P
authors.initials: DP
authors.lastname: Steensma
mesh_terms: D005293:Ferritins / Q000097:blood; D006801:Humans; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000517:prevention & control; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D012307:Risk Factors
chemical_list: D007502:Iron Chelating Agents; D005293:Ferritins; D007501:Iron